The use of GLP-1 meds — made popular by Ozempic (NVO) — among U.S. adults without diabetes more than tripled between 2018 and 2022, with annual spending surging from $1.6 billion to $5.8 billion.Read more…
Read More
The use of GLP-1 meds — made popular by Ozempic (NVO) — among U.S. adults without diabetes more than tripled between 2018 and 2022, with annual spending surging from $1.6 billion to $5.8 billion.Read more…
Read More
Enter your details below to save your shopping cart for later. And, who knows, maybe we will even send you a sweet discount code :)
Allow notifications to get real-time updates about your shopping cart and who knows, you may even receive a sweet discount code 😊